Cargando…

Prognostic value of proliferation assay in the luminal, HER2-positive, and triple-negative biologic classes of breast cancer

INTRODUCTION: Although the prognostic significance of proliferation in early invasive breast cancer has been recognized for a long time, recent gene-expression profiling studies have reemphasized its biologic and prognostic value and the potential application of its assessment in routine practice, p...

Descripción completa

Detalles Bibliográficos
Autores principales:	Aleskandarany, Mohammed A, Green, Andrew R, Benhasouna, Ahmed A, Barros, Fabricio F, Neal, Keith, Reis-Filho, Jorge S, Ellis, Ian O, Rakha, Emad A
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2012
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3496118/ https://www.ncbi.nlm.nih.gov/pubmed/22225836 http://dx.doi.org/10.1186/bcr3084

Ejemplares similares

Oestrogen-regulated protein SLC39A6: a biomarker of good prognosis in luminal breast cancer
por: Althobiti, Maryam, et al.
Publicado: (2021)

Novel immunohistochemistry-based signatures to predict metastatic site of triple-negative breast cancers
por: Klimov, Sergey, et al.
Publicado: (2017)

HER2/HER3 heterodimers and p21 expression are capable of predicting adjuvant trastuzumab response in HER2+ breast cancer
por: Green, Andrew R., et al.
Publicado: (2014)

MYC functions are specific in biological subtypes of breast cancer and confers resistance to endocrine therapy in luminal tumours
por: Green, Andrew R, et al.
Publicado: (2016)

Combined HER3-EGFR score in triple-negative breast cancer provides prognostic and predictive significance superior to individual biomarkers
por: Ogden, Angela, et al.
Publicado: (2020)

Refining the definition of HER2‐low class in invasive breast cancer
por: Atallah, Nehal M, et al.
Publicado: (2022)

MYC regulation of glutamine–proline regulatory axis is key in luminal B breast cancer
por: Craze, Madeleine L, et al.
Publicado: (2018)

Mediator complex (MED) 7: a biomarker associated with good prognosis in invasive breast cancer, especially ER+ luminal subtypes
por: Joseph, Chitra, et al.
Publicado: (2018)

Are triple-negative tumours and basal-like breast cancer synonymous?
por: Rakha, Emad A, et al.
Publicado: (2007)

PPFIA1 expression associates with poor response to endocrine treatment in luminal breast cancer
por: Alfarsi, Lutfi H., et al.
Publicado: (2020)

Biological and clinical significance of PARP1 protein expression in breast cancer
por: Green, Andrew R., et al.
Publicado: (2014)

Involvement of metformin and AMPK in the radioresponse and prognosis of luminal versus basal-like breast cancer treated with radiotherapy
por: Zhang, Yimin, et al.
Publicado: (2014)

DNA damage response markers are differentially expressed in BRCA-mutated breast cancers
por: Aleskandarany, Mohammed, et al.
Publicado: (2015)

Chemokine (C‐C motif) receptor 7 (CCR7) associates with the tumour immune microenvironment but not progression in invasive breast carcinoma
por: Sonbul, Sultan N, et al.
Publicado: (2017)

Clinicopathological utility of human epidermal growth factor receptor 2 (HER2)-heterogeneity for next-generation treatments of triple-negative breast cancer
por: Kurozumi, Sasagu, et al.
Publicado: (2021)

The prognostic significance of BMI1 expression in invasive breast cancer is dependent on its molecular subtypes
por: Althobiti, Maryam, et al.
Publicado: (2020)

The Biological and Clinical Significance of Glutaminase in Luminal Breast Cancer
por: Masisi, Brendah K., et al.
Publicado: (2021)

Ki67 assessment in invasive luminal breast cancer: a comparative study between different scoring methods
por: Lashen, Ayat, et al.
Publicado: (2022)

Investigating AP-2 and YY1 protein expression as a cause of high HER2 gene transcription in breast cancers with discordant HER2 gene amplification
por: Powe, Desmond G, et al.
Publicado: (2009)

Calpain system protein expression in basal-like and triple-negative invasive breast cancer
por: Storr, S. J., et al.
Publicado: (2012)

Caveolin 1 and Caveolin 2 are associated with breast cancer basal-like and triple-negative immunophenotype
por: Elsheikh, S E, et al.
Publicado: (2008)

Integrated Analysis of Key Differentially Expressed Genes Identifies DBN1 as a Predictive Marker of Response to Endocrine Therapy in Luminal Breast Cancer
por: Alfarsi, Lutfi H., et al.
Publicado: (2020)

Clinicopathologic and molecular predictors of axillary lymph node metastasis in early-stage breast cancer: a mathematical predictive model
por: Aleskandarany, MA, et al.
Publicado: (2010)

The amino acid transporter SLC7A5 confers a poor prognosis in the highly proliferative breast cancer subtypes and is a key therapeutic target in luminal B tumours
por: El Ansari, Rokaya, et al.
Publicado: (2018)

A Case Series Exploration of Multi-Regional Expression Heterogeneity in Triple-Negative Breast Cancer Patients
por: Xu, Qi, et al.
Publicado: (2022)

The clinical and biological significance of HER2 over-expression in breast ductal carcinoma in situ: a large study from a single institution
por: Miligy, Islam M., et al.
Publicado: (2019)

Machine learning-based prediction of breast cancer growth rate in vivo
por: Bhattarai, Shristi, et al.
Publicado: (2019)

ADA3 regulates normal and tumor mammary epithelial cell proliferation through c-MYC
por: Griffin, Nicolas I., et al.
Publicado: (2016)

Co-expression of nuclear P38 and hormone receptors is prognostic of good long-term clinical outcome in primary breast cancer and is linked to upregulation of DNA repair
por: Johnston, Simon J., et al.
Publicado: (2018)

Luminal B breast tumors are not HER2 positive
por: Bhargava, Rohit, et al.
Publicado: (2008)

HER2 status and disparities in luminal breast cancers
por: Holowatyj, Andreana N., et al.
Publicado: (2016)

Luminal B breast tumors are not HER2 positive – authors' response
por: Tamimi, Rulla M, et al.
Publicado: (2008)

Ki67 expression in invasive breast cancer: the use of tissue microarrays compared with whole tissue sections
por: Muftah, Abir A., et al.
Publicado: (2017)

Molecular pathology of the luminal class of urothelial tumors
por: Bernardo, Carina, et al.
Publicado: (2019)

The prognostic significance of wild-type isocitrate dehydrogenase 2 (IDH2) in breast cancer
por: Aljohani, Abrar I., et al.
Publicado: (2019)

Prognostic significance of KN motif and ankyrin repeat domains 1 (KANK1) in invasive breast cancer
por: Kariri, Yousif A., et al.
Publicado: (2019)

Luminal B, Human Epidermal Growth Factor Receptor 2 (HER2/neu), and Triple-Negative Breast Cancers Associated With a Better Chemotherapy Response Than Luminal A Breast Cancers in Postneoadjuvant Settings
por: Hashmi, Atif A, et al.
Publicado: (2023)

Histological grading of breast cancer on needle core biopsy: the role of immunohistochemical assessment of proliferation
por: Kwok, T’ng Chang, et al.
Publicado: (2010)

Clinical and prognostic profile of Her2neu positive (non-luminal) intrinsic breast cancer subtype: comparison with Her2neu positive luminal breast cancers
por: Hashmi, Atif Ali, et al.
Publicado: (2018)

High Mutation Burden in ER-Positive/HER2-Negative/Luminal Breast Cancers
por: Voutsadakis, Ioannis A.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_6b80ehp9muedgdhr7hrc2dsme0